Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Effectiveness, Acceptability and Feasibility of a Communication and Care Coordinator (CCC) Model in Facilitating Serious Illness Communication (SIC) and Care in Patients With Cancer (CCC-Cancer)

5 november 2026 bijgewerkt door: National Cancer Centre, Singapore

Evaluating the Effectiveness, Acceptability and Feasibility of a Communication and Care Coordinator (CCC) Model in Facilitating Serious Illness Communication (SIC) and Care in Patients With Cancer

The goal of this clinical trial is to evaluate the communication and care coordinator (CCC) model in a national cancer institute and assess the utility of the model in facilitating serious illness communication (SIC) and care for patients with cancer.

The study aims are:

  • To assess the effectiveness of the CCC model in improving patient outcomes.
  • To assess the effectiveness of the CCC model in increasing rates of SIC and advance care planning (ACP) record documentation.
  • To assess the acceptability of the CCC model to patients and clinicians.
  • To evaluate the feasibility of implementing a CCC model in oncology care.

Researchers will compare results from the CCC intervention arm and usual care arm, to see if the CCC model can help improve patient outcomes and facilitate SIC between patients and clinicians.

Patient participants will:

  • Follow the assignment of their clinician, who will be assigned randomly to either the usual care group or the intervention group.
  • Be assigned a CCC and receive 6 CCC sessions over the course of 3 months (if assigned to CCC intervention arm).
  • Complete 3 study assessment visits at baseline, Week 6, and 3 months
  • Be invited to a one-time interview to share their study experience (optional, if selected and if in CCC intervention arm).

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Timely SIC may facilitate earlier preferred plan of care documentation and improve patients' sense of peacefulness, hopefulness, and connectedness with their clinicians. The primary goal of the study is to evaluate the CCC model in a national cancer institute and assess the utility of the model in facilitating SIC and care for patients with cancer through a stepped wedge cluster randomized trial. This approach delivers crucial, empirical insights into how SIC can be efficiently and effectively delivered and potentially allow larger scale implementation and dissemination of the CCC model in Singapore, as an effective model for delivering patient support and facilitating patient-clinician communication in patients with advanced cancer.

Studietype

Ingrijpend

Inschrijving (Geschat)

560

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

  • Naam: Benton PT TAM, MSc

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

21 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

Patient Participants

  • Aged 21 and above
  • Diagnosed with (a) advanced cancer (stage 3 or 4) or (b) non-advanced cancer, but at high risk of recurrence
  • Able to speak English or Chinese, irrespective of race

Clinicians

  • Oncologists who are at least of designation of associate consultant and above in NCCS

Exclusion Criteria:

Patient Participants

  • Disoriented and thus not able to sign informed consent
  • Diagnosed with untreated hearing or visual loss or psychiatric illness
  • Active suicidal ideation

Clinicians

  • Overseas/not practising in Singapore for a significant amount of time

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Onderzoek naar gezondheidsdiensten
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: CCC Intervention Arm

Each participant will be assigned a CCC and receive 6 CCC sessions over the course of 3 months.

CCC sessions will be on exploring participant's illness journey thus far, their concerns, values and priorities.

Geen tussenkomst: Usual Care Arm

Each participant will continue to be followed by the oncologist and receive usual care but will not receive CCC intervention.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Communication Quality
Tijdsspanne: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.

Feeling Heard and Understood Survey (FHU) is a validated 4-item scale that has been used in palliative care to measure effectiveness of the SIC conversations and the value of the therapeutic relationship between the care team and the patient. The lowest possible score is 0 and the highest possible score is 16, with a higher score indicating that the care team listens well, respects patient's needs, and provides clear communication.

Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Quality of Life per FACT-G7
Tijdsspanne: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.

Functional Assessment of Cancer Therapy-General-7 Item version (FACT-G7) is a 7-item questionnaire designed to quickly and effectively capture the most relevant issues to cancer. FACT-G7 scores could potentially range from 0-28, with a higher score indicating a better quality of life.

Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Health Utility
Tijdsspanne: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.

EuroQOL Group 5-Dimension (EQ-5D-5L) contains a 5-item descriptive system measuring 5 dimensions: mobility, self-care, usual activities, pain/ discomfort, anxiety/ depression; a visual analogue scale (VAS) measuring overall health status. EQ-5D Index Value (Utility Score) ranges from 0 to 1.0 with higher value indicating better health-related quality of life. The VAS ranges from 0 to 100, with higher scores reflecting better self-rated health.

Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Spiritual Well-Being
Tijdsspanne: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.

Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale (FACIT-Sp-12) is a validated 12-item survey that is commonly used in the palliative care setting. It has 3 subscales (meaning, peace and faith). Scores in each subscale can potentially range from 0-16 and the total scores can range from 0-48. A higher score indicates greater spiritual well-being, better ability to find purpose in life and drawing comfort from spiritual resources.

Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Healthcare Utilization - Rate of Unplanned Acute Hospital Utilization
Tijdsspanne: From Study Enrolment to 3 months Post Enrolment.

The rate of unplanned acute hospital utilization through the emergency department during the study will be collected.

From Study Enrolment to 3 months Post Enrolment.
Healthcare utilization - Length of hospital stay
Tijdsspanne: From Study Enrolment until Date of Death, up to 3 years.

Data on the length of stay in hospital (bed days) will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Hospital Bill
Tijdsspanne: From Study Enrolment until Date of Death, up to 3 years.

Data on hospital bill size will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Type of oncological treatment
Tijdsspanne: From 3 months prior to study enrolment until 3 months after study enrolment.

Data on the type of oncological treatment used will be collected.

From 3 months prior to study enrolment until 3 months after study enrolment.
Healthcare utilization - Chemotherapy usage (line)
Tijdsspanne: From Study Enrolment until Date of Death, up to 3 years.

Data on the line of chemotherapy (first, second or third or subsequent (fourth and onwards)) will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Intensive care unit visit
Tijdsspanne: From Study Enrolment until Date of Death, up to 3 years.

Data on the number of intensive care unit visits will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Length of intensive care unit visit
Tijdsspanne: From Study Enrolment until Date of Death, up to 3 years.

Data on the length of intensive care unit visits will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - High dependency unit visit
Tijdsspanne: From Study Enrolment until Date of Death, up to 3 years.

Data on the number of high dependency unit visits will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Length of high dependency unit visit
Tijdsspanne: From Study Enrolment until Date of Death, up to 3 years.

Data on the length of high dependency unit visits will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Location of death
Tijdsspanne: From Study Enrolment until Date of Death, up to 3 years.

Data on the location of death will be collected.

From Study Enrolment until Date of Death, up to 3 years.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Acceptability - Satisfaction
Tijdsspanne: 3 months Post Enrolment.

Client satisfaction survey is a 4-item, 4-point scale survey in which patients provide ratings on their satisfaction with the intervention, and their views on its relevance, timeliness, and impact. It has been validated in research studies in the outpatient setting around mental health support. Score can range from 4-16, with a higher score indicating greater client satisfaction.

3 months Post Enrolment.
Feasibility - Approach-to-Enrolment Rates
Tijdsspanne: From Commencement of Study Recruitment till the End of Recruitment, up to 24 months.

Approach-to-enrolment rates - where feasibility is defined that at least 60% of those patients approached could be enrolled into the study.

From Commencement of Study Recruitment till the End of Recruitment, up to 24 months.
Feasibility - Patient Retention Rate
Tijdsspanne: Baseline through Study Completion, estimated as up to 3 years.

Patient retention rate - where feasibility is defined that at least 80% of enrolled patients will be able to participate in the study for the planned study duration (3 months).

Baseline through Study Completion, estimated as up to 3 years.
Effectiveness - SIC and ACP documentation
Tijdsspanne: From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years

The number of SIC and ACP documentation per clinician per enrolled patient during the study duration will be tracked during the intervention period(s) and during the control period(s). Clinical notes will also be read to evaluate if there was relevant documentation by clinician on SIC related issues.

From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years
Effectiveness - Time spent
Tijdsspanne: From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years

Time spent by CCC in this model and estimated time spent by clinicians on SICs will be collected.

From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years
Acceptability - Clinician experience
Tijdsspanne: At end of intervention period (28th month).

Clinicians will be surveyed using a modified version of the Clinician Experience Survey (CES). The original CES was developed by Ariadne Labs for the purposes of assessing clinicians perceived feasibility and barriers in engaging patients in SIC. The researchers will modify the CES to form a 4-item scale (score range 4-16), with a higher score indicating greater clinicians' satisfaction with the CCC intervention.

At end of intervention period (28th month).

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie stoel: Shirlyn NEO Hui Shan, MD, PhD, National Cancer Centre, Singapore

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

5 november 2026

Primaire voltooiing (Geschat)

30 juni 2028

Studie voltooiing (Geschat)

30 juni 2029

Studieregistratiedata

Eerst ingediend

21 juli 2026

Eerst ingediend dat voldeed aan de QC-criteria

24 juli 2026

Eerst geplaatst (Werkelijk)

29 juli 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

10 november 2026

Laatste update ingediend die voldeed aan QC-criteria

5 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 2026-1239

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .